Literature DB >> 9122736

Topotecan: an important new drug in the management of ovarian cancer.

M Markman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9122736

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  3 in total

1.  Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.

Authors:  Emilio Esteban Gonzalez; Noemi Villanueva; Joaquin Fra; Jose Pablo Berros; Paula Jimenez; María Luque; Isabel Muñiz; Pilar Blay; Yolanda Fernandez; José María Vieitez; Carolina Muriel; Miguel Sanmamed; Pablo Pardo Coto; Marta Izquierdo; Enrique Estrada; Angel J Lacave
Journal:  Invest New Drugs       Date:  2010-05-13       Impact factor: 3.850

2.  Physiologically based pharmacokinetic model for topotecan in mice.

Authors:  Dhaval K Shah; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-20       Impact factor: 2.745

3.  Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice.

Authors:  Jin Chen; Qiang Lu; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-09-21       Impact factor: 2.410
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.